Quest Diagnostics Inc (DGX)
Juste valeurFondamental
73
Prix
$231.91
Capitalisation boursière
$26.23B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users
Labcorp is the other national US clinical laboratory network, selling the same routine and specialty test menu to the same physicians, hospitals, health plans and employers, and competing directly for the same managed-care contracts and hospital outreach deals.
Through Sonic Healthcare USA it runs a large network of regional clinical laboratories serving American physicians and hospitals, the same customers Quest bids for, and it is also Quest's main rival in Canada after the LifeLabs acquisition.
As one of the largest US reference laboratories, it takes in specialty and esoteric testing sent out by hospitals and physician practices across the country, the higher-value volume Quest's advanced diagnostics business targets.
A non-profit national reference laboratory owned by the University of Utah that competes for the same hospital and health-system send-out testing contracts Quest pursues with its hospital lab services.
It sells oncology and molecular testing to US pathologists, oncologists and hospitals, overlapping with the cancer and genetic testing line Quest is expanding within its advanced diagnostics.
Its clinical diagnostics division runs routine and specialty testing laboratories, including in the United States, competing for the same physician and hospital testing volumes as Quest.
Bilan & Liquidités
Chiffre d'affaires
$11.56B
12 derniers mois (au 30/06/2026)
Résultat net
$1.06B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$1.36B
Capitaux propres totaux
$7.17B
Passif total
$9.02B
Ratio de liquidité général
1.59
Couverture des intérêts
6.37
Dette/EBITDA
3.00
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$222.23
Prix actuel
$231.91
Marge de sécurité
-4.4%
Fourchette de juste valeur
$155.33 - $289.13
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
24.74
ROE
13.8%
Ratio P/B
3.42
P/FCF
19.07
Marge brute
33.1%
ROIC
8.5%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
8.5%
WACC
7.1%
ROIC − WACC
+1.4 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (20)
- EPS shows upward trend
- EPS CAGR 9.39%
- Price CAGR 9.85%
- ROIC 8.5%
- Gross Margin 33.1%
- P/FCF 19.07
- Debt/Equity ratio
- Operating Margin 14.1%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 14.5%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 4.8%
- Earnings Quality (OCF/NI) 1.79
- Share Dilution 0.1%
- Net Margin Trend 9.2% vs 9.0%
- Piotroski F-Score 8/9
Échoué (6)
- P/B Ratio 3.42
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 3.2%
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. James E. Davis | Chairman, CEO & President | 62 |
| Mr. Sam A. Samad | Executive VP & CFO | 55 |
| Mr. Michael E. Prevoznik J.D. | Senior VP & General Counsel | 63 |
| Ms. Catherine T. Doherty | Executive Vice President of Regional Businesses | 62 |
| Mr. Karthik Kuppusamy Ph.D. | Senior Vice President of Clinical Solutions | 55 |
| Mr. Michael J. Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 58 |
| Mr. Murali Balakumar | Senior VP and Chief Information & Digital Officer | - |
| Ms. Damini Chokshi | Vice President of Investor Relations | - |
| Ms. Kristin Lee Wallace Esq. | Senior VP & Chief Compliance Officer | - |
| Mr. Garry Clark | Senior VP and Chief Marketing & Communications Officer | - |
Risque d'audit
6
Risque du conseil
7
Risque de rémunération
2
Risque droits des actionnaires
2
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-26
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-07-23
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-07-23
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for DGX, sourced from Markets Gazette.